Skip to Content

'
Linda S Elting, Dr P H

Present Title & Affiliation

Primary Appointment

Professor, Department of Health Services Research, Division of OVP, Cancer Prevention and Population Sciences, The University of Texas MD Anderson Cancer Center, Houston, TX

Dual/Joint/Adjunct Appointment

Associate Member, The University of Texas Graduate School of Biomedical Sciences, Houston, TX
Professor, Department of Health Disparities Research, Division of Cancer Prevention and Population Sciences, The University of Texas MD Anderson Cancer Center, Houston, TX

Education & Training

Degree-Granting Education

1988 The University of Texas School of Public Health, Houston, TX, DrPH, Epidemiology, Biometry, Infectious Diseases
1981 The University of Texas School of Public Health, Houston, TX, MPH, Disease Control
1974 Houston Baptist University, Houston, TX, BS, Nursing

Board Certifications

1/1986 Association of Practitioners in Infection Control - Certified in Infection Control

Experience/Service

Academic Appointments

Professor, Department of Biostatistics, Division of Quantitative Sciences, The University of Texas MD Anderson Cancer Center, Houston, TX, 2004-2013
Associate Professor, Department of Biostatistics and Applied Mathematics, The University of Texas M. D. Anderson Cancer Center, Houston, TX, 2001-2004
Research Assistant, Research Nurse Supervisor, Project Coordinator, The University of Texas M. D. Anderson Cancer Center, Houston, TX, 1976-1988
Staff Nurse, Hermann Hospital, Houston, TX, 1975-1976
Health Educator, Harris County Center for the Retarded, Adult Residential Facility, Houston, TX, 1974-1975
Coding and Data Collection, Department of Epidemiology, The University of Texas M.D. Anderson Cancer Center, Houston, TX, 1970-1971

Administrative Appointments/Responsibilities

Chairman, Institutional Review Board IV, The University of Texas MD Anderson Cancer Center, Houston, TX, 9/2005-present
Vice-Chairman, Institutional Review Board, The University of Texas M. D. Anderson Cancer Center, Houston, TX, 9/2003-8/2005
Chief, Section of Health Services Research, Department of Biostatistics & Applied Mathematics, The University of Texas MD Anderson Cancer Center, Houston, TX, 6/2001-present
Director of Research, Section of General Internal Medicine, The University of Texas M. D. Anderson Cancer Center, Houston, TX, 1/1998-1/1999
Director, Clinical Epidemiology and Informatics, Ambulatory & Supportive Care Oncology Research Program, The University of Texas M. D. Anderson Cancer Center, Houston, TX, 1/1992-1/1998

Other Appointments/Responsibilities

Design, Patient Satisfaction Survey for the Ambulatory Treatment Center and General Internal Medicine Clinics, Houston, 1/1997-1/1999
Design and Management, Ambulatory Treatment Center and General Internal Medicine Information Systems, Houston, 1/1994-1/1999

Institutional Committee Activities

Member, Data and Prioritization Committee for Comprehensive Cancer Control, 12/2008-present
Member, Comprehensive Cancer Strategic Plan Steering Committee, 9/2008-present
Chairman, Institutional Review Board 4, 9/2005-present
Member, Biostatistics Faculty Search Committee, 1/2004-1/2005
Vice-Chairman, Institution Review Board, 9/2003-9/2005
Member, Education Subcommittee for Faculty Achievement Awards, 9/2003-12/2003
Chairman, IRB Task force to develop standard operating procedures for members conflicts of interest, 8/2003-1/2004
Member, Search Committee, Department of Health Disparities Research, 1/2003-1/2004
Member, Department of Epidemiology Faculty Search Committee, 1/2003-1/2004
Member, Center for Research in Minority Health, Internal Advisory Board, 1/2002-present
Member, Search Committee, Head, Division of Internal Medicine, 1/2001-1/2002
Chairman, Economist Faculty Search Committee, 1/2001-1/2002
Member, Prostate Outcomes Faculty Search Committee, UT M.D Anderson Cancer Center, 1/2001-1/2002
Member, Cancer Prevention Subcommittee for the Faculty Achievement Awards, 1/2001-12/2001
Faculty Senate Representative, Employee Satisfaction Steering Committee, 1/2000-1/2002
Member, Faculty Senate, 1/1999-1/2002
Member, Faculty Senate - Research Affairs Committee, 1/1999-1/2002
Member, Study Section Review Committee for Clinical, Translational and Population-Based Research Projects, 1/1999-1/2002
Member, Division of Medicine, Executive Council - Research Sub-Committee, 1/1999-12/1999
Member, Surveillance Committee (Institutional Review Board), 9/1997-present
Co-Chairman, Psychosocial, Behavioral and Health Services Research Review Committee, 9/1997-1/2001
Member, Health Services Research Working Group, 1/1994-1/1998
Chairman, Quality of Life Steering Committee, 1/1994-1/1995

Honors and Awards

2012 Texas Business Women's Award, Texas Business Women Inc.
2011-present Senior Fellow, Sealy Center on Aging, The University of Texas Medical Branch
2011 MASCC Distinguished Achievement Award, Multinational Association of Supportive Care in Cancer
2006 Outstanding Research Presentation, Texas Public Health Association Annual Meeting
2005 Best Research Presentation, Texas Public Health Association Annual Meeting
2003 Best Research Presentation, Texas Public Health Association Annual Meeting
2001 Best Research Presentation, Kelsey Research Foundation Health Services and Outcomes Research Conference
2000 Selected to attend Senior Women in Medicine Professional Development Seminar, Association of American Medical Colleges
1997 Best Proffered Paper Award, Annual Meeting, Multinational Association for Supportive Care in Cancer

Selected Publications

Peer-Reviewed Original Research Articles
1. Elting L, Chang YC. Costs of oral complications of emerging cancer therapies: Current estimates and a blueprint for future study. JNCI. In Press.
2. Eberth JM, Eschbach K, Morris JS, Nguyen HT, Hossain MM, Elting LS. Geographic disparities in mammography capacity in the South: a longitudinal assessment of supply and demand. Health Services Research. In Press.
3. Eberth JM, Prarelkar P, Nguyen H, Sun C, Irvin-Vidrine J, Elting LS. The Human and Economic Burden of Cervical Cancer in Texas. Texas Public Health Journal. In Press.
4. Freeman J, Elting L. Training Core- Principal Investigators. Texas Public Health Journal. In Press.
5. Elting LS, Chang YC, Parelkar P, Boers-Doets CB, Michelet M, Hita G, Rouleau T, Cooksley C, Halm J, Vithala M, Bossi P, Escalante C, Brennan MT, On behalf of the Mucositis Study Group of the Multinational Association of Supportive Care in Cancer/International Society of Oral Oncology (MASCC/ISOO). Risk of oral and gastrointestinal mucosal injury among patients receiving selected targeted agents: A meta-analysis. Support Care Cancer. e-Pub 5/2/2013. PMID: 23636648.
6. Gomez DR, Liao KP, Giordano S, Nguyen H, Smith BD, Elting LS. Adherence to national guidelines for antiemesis prophylaxis in patients undergoing chemotherapy for lung cancer: a population-based study". Cancer 119(7):1428-36, 4/2013. e-Pub 12/2012. PMID: 23212885.
7. Tan A, Kuo YF, Elting LS, Goodwin JS. Refining physician quality indicators for screening mammography in older women: distinguishing appropriate use from overuse. J Am Geriatr Soc 61(3):380-7, 3/2013. e-Pub 3/2013. PMCID: PMC3602404.
8. Guadagnolo BA, Liao KP, Elting L, Giordano S, Buchholz TA, Shih YC. Use of radiation therapy in the last 30 days of life among a large population-based cohort of elderly patients in the United States. J Clin Oncol 31(1):80-7, 1/1/2013. e-Pub 11/19/2012. PMCID: PMC3530693.
9. Parelkar PP, Hoang NT, Holmes H, Elting L. Adherence to physical activity guidelines after cancer diagnosis among cancer survivors ages 45-64 in Texas. Texas Public Health Journal 65(1):32, 1/2013.
10. Beadle BM, Liao KP, Chambers MS, Elting LS, Buchholz TA, Kian Ang K, Garden AS, Guadagnolo BA. Evaluating the impact of patient, tumor, and treatment characteristics on the development of jaw complications in patients treated for oral cancers: A SEER-Medicare analysis. Head Neck. e-Pub 11/2012. PMID: 23150453.
11. Holmes HM, Luo R, Hanlon JT, Elting LS, Suarez-Almazor M, Goodwin JS. Ethnic Disparities in Adherence to Antihypertensive Medications of Medicare Part D Beneficiaries. J Am Geriatr Soc 60(7):1298-303, 7/2012. e-Pub 6/15/2012. PMCID: PMC3396714.
12. Shih YC, Ward JF, Pettaway CA, Xu Y, Matin SF, Davis JW, Thompson BP, Elting LS. Comparative effectiveness, cost, and utilization of radical prostatectomy among young men within managed care insurance plans. Value Health 15(2):367-75, Mar-Apr, 3/2012. e-Pub 12/16/2011. PMID: 22433769.
13. Vissink A, Mitchell JB, Baum BJ, Limesand KH, Jensen SB, Fox PC, Elting LS, Langendijk JA, Coppes RP, Reyland ME. Clinical management of salivary gland hypofunction and xerostomia in head-and-neck cancer patients: successes and barriers. Int J Radiat Oncol Biol Phys 78(4):983-91, 11/15/2010. PMCID: PMC2964345.
14. Avritscher EB, Shih YC, Sun CC, Gralla RJ, Grunberg SM, Xu Y, Elting LS. Cost-Utility Analysis of Palonosetron-Based Therapy in Preventing Emesis Among Breast Cancer Patients. J Support Oncol 8(6):242-251, Nov-Dec, 11/2010. PMID: 21265391.
15. Jones JA, Fayad LE, Elting LS, Rodriguez MA. Body mass index and outcomes in patients receiving chemotherapy for intermediate-grade B-cell non-Hodgkin lymphoma. Leuk Lymphoma 51(9):1649-57, 9/2010. PMID: 20807093.
16. Migliorati CA, Woo SB, Hewson I, Barasch A, Elting LS, Spijkervet FK, Brennan MT, Bisphosphonate Osteonecrosis Section, Oral Care Study Group, Multinational Association of Supportive Care in Cancer (MASCC)/International Society of Oral Oncology (ISOO). A systematic review of bisphosphonate osteonecrosis (BON) in cancer. Support Care Cancer 18(8):1099-106, 8/2010. e-Pub 4/22/2010. PMID: 20411279.
17. Hong CH, Napeñas JJ, Hodgson BD, Stokman MA, Mathers-Stauffer V, Elting LS, Spijkervet FK, Brennan MT, Dental Disease Section, Oral Care Study Group, Multi-national Association of Supportive Care in Cancer (MASCC)/International Society of Oral Oncology (ISOO). A systematic review of dental disease in patients undergoing cancer therapy. Support Care Cancer 18(8):1007-21, 8/2010. e-Pub 5/7/2010. PMCID: PMC2914291.
18. Hovan AJ, Williams PM, Stevenson-Moore P, Wahlin YB, Ohrn KE, Elting LS, Spijkervet FK, Brennan MT, Dysgeusia Section, Oral Care Study Group, Multinational Association of Supportive Care in Cancer (MASCC)/International Society of Oral Oncology (ISOO). A systematic review of dysgeusia induced by cancer therapies. Support Care Cancer 18(8):1081-7, 8/2010. e-Pub 5/2010. PMID: 20495984.
19. Lalla RV, Latortue MC, Hong CH, Ariyawardana A, D'Amato-Palumbo S, Fischer DJ, Martof A, Nicolatou-Galitis O, Patton LL, Elting LS, Spijkervet FK, Brennan MT, Fungal Infections Section, Oral Care Study Group, Multinational Association of Supportive Care in Cancer (MASCC)/International Society of Oral Oncology (ISOO). A systematic review of oral fungal infections in patients receiving cancer therapy. Support Care Cancer 18(8):985-92, 8/2010. e-Pub 5/8/2010. PMCID: PMC2914797.
20. Epstein JB, Hong C, Logan RM, Barasch A, Gordon SM, Oberlee-Edwards L, McGuire D, Napenas JJ, Elting LS, Spijkervet FK, Brennan MT. A systematic review of orofacial pain in patients receiving cancer therapy. Support Care Cancer 18(8):1023-31, 8/2010. e-Pub 6/11/2010. PMID: 20544225.
21. Jensen SB, Pedersen AM, Vissink A, Andersen E, Brown CG, Davies AN, Dutilh J, Fulton JS, Jankovic L, Lopes NN, Mello AL, Muniz LV, Murdoch-Kinch CA, Nair RG, Napeñas JJ, Nogueira-Rodrigues A, Saunders D, Stirling B, von Bültzingslöwen I, Weikel DS, Elting LS, Spijkervet FK, Brennan MT, Salivary Gland Hypofunction/Xerostomia Section, Oral Care Study Group, Multinational Association of Supportive Care in Cancer (MASCC)/International Society of Oral Oncology (ISOO). A systematic review of salivary gland hypofunction and xerostomia induced by cancer therapies: management strategies and economic impact. Support Care Cancer 18(8):1061-79, 8/2010. e-Pub 3/25/2010. PMID: 20333412.
22. Jensen SB, Pedersen AM, Vissink A, Andersen E, Brown CG, Davies AN, Dutilh J, Fulton JS, Jankovic L, Lopes NN, Mello AL, Muniz LV, Murdoch-Kinch CA, Nair RG, Napeñas JJ, Nogueira-Rodrigues A, Saunders D, Stirling B, von Bültzingslöwen I, Weikel DS, Elting LS, Spijkervet FK, Brennan MT, Salivary Gland Hypofunction/Xerostomia Section, Oral Care Study Group, Multinational Association of Supportive Care in Cancer (MASCC)/International Society of Oral Oncology (ISOO). A systematic review of salivary gland hypofunction and xerostomia induced by cancer therapies: prevalence, severity and impact on quality of life. Support Care Cancer 18(8):1039-60, 8/2010. e-Pub 3/17/2010. PMID: 20237805.
23. Bensadoun RJ, Riesenbeck D, Lockhart PB, Elting LS, Spijkervet FK, Brennan MT, Trismus Section, Oral Care Study Group, Multinational Association for Supportive Care in Cancer (MASCC)/International Society of Oral Oncology (ISOO). A systematic review of trismus induced by cancer therapies in head and neck cancer patients. Support Care Cancer 18(8):1033-8, 8/2010. e-Pub 3/6/2010. PMID: 20213237.
24. Elad S, Zadik Y, Hewson I, Hovan A, Correa ME, Logan R, Elting LS, Spijkervet FK, Brennan MT, Viral Infections Section, Oral Care Study Group, Multinational Association of Supportive Care in Cancer (MASCC)/International Society of Oral Oncology (ISOO). A systematic review of viral infections associated with oral involvement in cancer patients: a spotlight on Herpesviridea. Support Care Cancer 18(8):993-1006, 8/2010. e-Pub 6/11/2010. PMID: 20544224.
25. Peterson DE, Doerr W, Hovan A, Pinto A, Saunders D, Elting LS, Spijkervet FK, Brennan MT. Osteoradionecrosis in cancer patients: the evidence base for treatment-dependent frequency, current management strategies, and future studies. Support Care Cancer 18(8):1089-98, 8/2010. e-Pub 6/6/2010. PMID: 20526784.
26. Brennan MT, Spijkervet FK, Elting LS. Systematic reviews and guidelines for oral complications of cancer therapies: current challenges and future opportunities. Support Care Cancer 18(8):977-8, 8/2010. e-Pub 3/10/2010. PMID: 20217147.
27. Brennan MT, Elting LS, Spijkervet FK. Systematic reviews of oral complications from cancer therapies, oral care study group, MASCC/ISOO: Methodology and Quality of the Literature. Support Care Cancer 18(8):979-84, 8/2010. e-Pub 3/2010. PMID: 20306090.
28. Shih YCT, Elting LS, Halpern MT. Factors associated with immunotherapy use among newly diagnosed cancer patients. Medical Care 47(9):948-58, 1/2010.
29. Shih YC, Elting LS, Pavluck AL, Stewart A, Halpern MT. Immunotherapy in the initial treatment of newly diagnosed cancer patients: utilization trend and cost projections for non-Hodgkin's lymphoma, metastatic breast cancer, and metastatic colorectal cancer. Cancer Invest 28(1):46-53, 1/2010. PMID: 19995227.
30. Elting LS, Cooksley CD, Bekele BN, Giordano SH, Shih YC, Lovell KK, Avritscher EB, Theriault R. Mammography Capacity: Impact on Screening Rates and Breast Cancer Stage at Diagnosis. Am J Prev Med 37(2):102-8, 8/2009. e-Pub 6/2009. PMID: 19524392.
31. Cooksley CD, Avritscher EB, Rolston KV, Elting LS. Hospitalizations for infection in cancer patients: impact of an aging population. Support Care Cancer 17(5):547-54, 5/2009. e-Pub 11/2008. PMID: 18982364.
32. Shih YC, Xu Y, Cormier JN, Giordano S, Ridner SH, Buchholz TA, Perkins GH, Elting LS. Incidence, Treatment Costs, and Complications of Lymphedema After Breast Cancer Among Women of Working Age: A 2-Year Follow-Up Study. J Clin Oncol 27(12):2007-14, 4/2009. e-Pub 3/2009. PMID: 19289624.
33. Elting LS, Keefe DM, Sonis ST, Garden AS, Spijkervet FK, Barasch A, Tischler RB, Canty TP, Kudrimoti MK, Vera-Llonch M, Vera-Llonch M. Patient-reported measurements of oral mucositis in head and neck cancer patients treated with radiotherapy with or without chemotherapy: demonstration of increased frequency, severity, resistance to palliation, and impact on quality of life. Cancer 113(10):2704-13, 11/2008. PMID: 18973181.
34. Cárdenas-Turanzas M, Tovalín-Ahumada H, Carrillo MT, Paéz-Aguirre S, Elting L. The place of death of children with cancer in the metropolitan areas of Mexico. J Palliat Med 11(7):973-9, 9/2008. PMID: 18788957.
35. Cooksley CD, Avritscher EB, Grossman HB, Sabichi AL, Dinney CP, Pettaway C, Elting LS. Clinical model of cost of bladder cancer in the elderly. Urology 71(3):519-25, 3/2008. PMID: 18342201.
36. Cárdenas-Turanzas M, Cooksley C, Kamat AM, Pettaway CA, Elting LS. Gender and age differences in blood utilization and length of stay in radical cystectomy: a population-based study. Int Urol Nephrol 40(4):893-9, 3/2008. PMID: 18317944.
37. Jones JA, Qazilbash MH, Shih YC, Cantor SB, Cooksley CD, Elting LS. In-hospital complications of autologous hematopoietic stem cell transplantation for lymphoid malignancies: clinical and economic outcomes from the Nationwide Inpatient Sample. Cancer 112(5):1096-105, 3/2008. PMID: 18286506.
38. Elting LS, Lu C, Escalante CP, Giordano SH, Trent JC, Cooksley C, Avritscher EB, Shih YC, Ensor J, Bekele BN, Gralla RJ, Talcott JA, Rolston K. Outcomes and cost of outpatient or inpatient management of 712 patients with febrile neutropenia. J Clin Oncol 26(4):606-11, 2/2008. PMID: 18235119.
39. Shih YC, Elting LS, Levin B. Disparities in colorectal screening between US-born and foreign-born populations: evidence from the 2000 National Health Interview Survey. J Cancer Educ 23(1):18-25, Jan-Mar, 1/2008. PMID: 18444042.
40. Elting LS, Avritscher EB, Cooksley CD, Cardenas-Turanzas M, Garden AS, Chambers MS. Psychosocial and Economic Impact of Cancer. Dent Clin North Am 52(1):231-252, 1/2008. PMID: 18154872.
41. Tina Shih YC, Xu Y, Elting LS. Costs of Uncontrolled Chemotherapy-Induced Nausea and Vomiting Among Working-Age Cancer Patients Receiving Highly or Moderately Emetogenic Chemotherapy. Cancer 110(3):678-685, 8/2007. PMID: 17567835.
42. Elting LS, Shih YC, Stiff PJ, Bensinger W, Cantor SB, Cooksley C, Spielberger R, Emmanoulides C. Economic Impact of Palifermin on the Costs of Hospitalization for Autologous Hematopoietic Stem-Cell Transplant: Analysis of Phase 3 Trial Results. Biol Blood Marrow Transplant 13(7):806-13, 7/2007. PMID: 17580258.
43. Elting LS, Cooksley CD, Chambers MS, Garden AS. Risk, outcomes, and costs of radiation-induced oral mucositis among patients with head-and-neck malignancies. Int J Radiat Oncol Biol Phys 68(4):1110-20, 7/2007. PMID: 17398022.
44. Avritscher EB, Cooksley CD, Geraci JM, Bekele BN, Cantor SB, Rolston KV, Elting LS. Cost-effectiveness of influenza vaccination in working-age cancer patients. Cancer 109(11):2357-64, 6/2007. PMID: 17457827.
45. Smith DL, Elting LS, Learn PA, Raut CP, Mansfield PF. Factors Influencing the Volume-Outcome Relationship in Gastrectomies: A Population-Based Study. Ann Surg Oncol 14(6):1846-52, 6/2007. PMID: 17406947.
46. Cárdenas-Turanzas M, Carrillo MT, Tovalín-Ahumada H, Elting L. Factors associated with place of death of cancer patients in the Mexico City Metropolitan area. Support Care Cancer 15(3):243-9, 2007. PMID: 17021856.
47. Keefe DM, Schubert MM, Elting LS, Sonis ST, Epstein JB, Raber-Durlacher JE, Migliorati CA, McGuire DB, Hutchins RD, Peterson DE, Peterson DE. Updated clinical practice guidelines for the prevention and treatment of mucositis. Cancer 109(5):820-31, 2007. PMID: 17236223.
48. Avritscher EB, Cooksley CD, Grossman HB, Sabichi AL, Hamblin L, Dinney CP, Elting LS. Clinical model of lifetime cost of treating bladder cancer and associated complications. Urology 68(3):549-53, 9/2006. PMID: 16979735.
49. Shih YC, Zhao L, Elting LS. Does Medicare coverage of colonoscopy reduce racial/ethnic disparities in cancer screening among the elderly? Health Aff (Millwood) 25(4):1153-62, Jul-Aug, 7/2006. PMID: 16835198.
50. Migliorati CA, Siegel MA, Elting LS. Bisphosphonate-associated osteonecrosis: a long-term complication of bisphosphonate treatment. Lancet Oncol 7(6):508-14, 6/2006. PMID: 16750501.
51. Jones JA, Avritscher EB, Cooksley CD, Michelet M, Bekele BN, Elting LS. Epidemiology of treatment-associated mucosal injury after treatment with newer regimens for lymphoma, breast, lung, or colorectal cancer. Support Care Cancer 14(6):505-15, 6/2006. PMID: 16601950.
52. Elting LS, Cooksley C, Bekele BN, Frumovitz M, Avritscher EB, Sun C, Bodurka DC. Generalizability of cancer clinical trial results: prognostic differences between participants and nonparticipants. Cancer 106(11):2452-8, 6/2006. PMID: 16639738.
53. Rolston KV, Manzullo EF, Elting LS, Frisbee-Hume SE, McMahon L, Theriault RL, Patel S, Benjamin RS. Once daily, oral, outpatient quinolone monotherapy for low-risk cancer patients with fever and neutropenia: a pilot study of 40 patients based on validated risk-prediction rules. Cancer 106(11):2489-94, 6/2006. PMID: 16628654.
54. Elting LS, Fortner BV, Bosserman L, Houts AC, Schwartzberg L. If at first you don't succeed, don't quit, try again: The Centers For Medicare and Medicaid Services demonstration project on quality of care--2005 and 2006. J Support Oncol 4(3):147-51, 3/2006. PMID: 16553141.
55. Cárdenas-Turanzas M, Cooksley C, Pettaway CA, Sabichi A, Grossman HB, Elting L. Comparative outcomes of bladder cancer. Obstet Gynecol 108(1):169-175, 2006. PMID: 16816072.
56. Cella D, Beaumont JL, Webster KA, Lai JS, Elting L. Measuring the concerns of cancer patients with low platelet counts: the Functional Assessment of Cancer Therapy--thrombocytopenia (FACT-Th) questionnaire. Support Care Cancer 14(12):1220-31, 2006. PMID: 16944221.
57. Elting LS, Pettaway C, Bekele BN, Grossman HB, Cooksley C, Avritscher EB, Saldin K, Dinney CP. Correlation between annual volume of cystectomy, professional staffing, and outcomes: A statewide, population-based study. Cancer 104(5):975-84, 9/2005. PMID: 16044400.
58. Cooksley CD, Avritscher EB, Bekele BN, Rolston KV, Geraci JM, Elting LS. Epidemiology and outcomes of serious influenza-related infections in the cancer population. Cancer 104(3):618-28, 8/2005. PMID: 15973737.
59. Mathew P, Elting L, Cooksley C, Owen S, Lin J. Cancer in an Incarcerated Population. Cancer 104(10):2197-20, 2005. PMID: 16206295.
60. Freifeld AG, Baden LR, Brown AE, Elting LS, Gelfand M, Greene JN, Ito JI, King E, Marcucci G, Montoya JG, Morris A, Noskin G, Rolston K, Schott AF, Segal B. Fever and neutropenia clinical practice guidelines. J Natl Compr Canc Netw 2(5):390-432, 9/2004. PMID: 19780251.
61. Elting LS, Escalante CP, Cooksley C, Avritscher EB, Kurtin D, Hamblin L, Khosla SG, Rivera E. Outcomes and cost of deep venous thrombosis among patients with cancer. Arch Intern Med 164(15):1653-61, Aug 9-23, 8/2004. PMID: 15302635.
62. Avritscher EB, Cantor SB, Shih YC, Escalante CP, Rivera E, Elting LS. Cost-minimization analysis of low-molecular-weight heparin (dalteparin) compared to unfractionated heparin for inpatient treatment of cancer patients with deep venous thrombosis. Support Care Cancer 12(7):531-6, 7/2004. PMID: 14986076.
63. Safdar A, Kaur H, Elting L, Rolston KV. Antimicrobial susceptibility of 128 Salmonella enterica serovar typhi and paratyphi A isolates from northern India. Chemotherapy 50(2):88-91, 6/2004. PMID: 15211083.
64. Rubenstein EB, Peterson DE, Schubert M, Keefe D, McGuire D, Epstein J, Elting LS, Fox PC, Cooksley C, Sonis ST. Clinical practice guidelines for the prevention and treatment of cancer therapy-induced oral and gastrointestinal mucositis. Cancer 100(9 Suppl):2026-46, 5/2004. PMID: 15108223.
65. Sonis ST, Elting LS, Keefe D, Peterson DE, Schubert M, Hauer-Jensen M, Bekele BN, Raber-Durlacher J, Donnelly JP, Rubenstein EB, Rubenstein EB, Rubenstein EB. Perspectives on cancer therapy-induced mucosal injury: pathogenesis, measurement, epidemiology, and consequences for patients. Cancer 100(9 Suppl):1995-2025, 5/2004. PMID: 15108222.
66. Elting LS, Shih YC. The economic burden of supportive care of cancer patients. Support Care Cancer 12(4):219-26, 4/2004. PMID: 14767748.
67. Avritscher EB, Cooksley CD, Elting LS. Scope and epidemiology of cancer therapy-induced oral and gastrointestinal mucositis. Semin Oncol Nurs 20(1):3-10, 2/2004. PMID: 15038511.
68. Elting, LS, Cooksley CD, Murakami Y, Avritscher EBS. Public Health Use of Inpatient Discharge Data: A Case Study of Reducing Burdens of Acute Respiratory Diseases in Texas with a Targeted Immunization Program. TPHA Journal 56:3-9, 2004. PMID: Not in Pub Med.
69. Adams JR, Elting LS, Lyman GH, George JN, Lembersky BC, Armitage JO, Demetri GD, Bennett CL. Use of erythropoietin in cancer patients: assessment of oncologists' practice patterns in the United States and other countries. Am J Med 116(1):28-34, 2004. PMID: 14706663.
70. Chau Q, Cantor SB, Caramel E, Hicks M, Kurtin D, Grover T, Elting LS. Cost-effectiveness of the bird's nest filter for preventing pulmonary embolism among patients with malignant brain tumors and deep venous thrombosis of the lower extremities. Support Care Cancer 11(12):795-9, 12/2003. PMID: 13680322.
71. Elting LS, Cooksley C, Chambers M, Cantor SB, Manzullo E, Rubenstein EB. The burdens of cancer therapy. Clinical and economic outcomes of chemotherapy-induced mucositis. Cancer 98(7):1531-9, 10/2003. PMID: 14508842.
72. Martin CG, Rubenstein EB, Elting LS, Kim YJ, Osoba D. Measuring chemotherapy-induced nausea and emesis. Cancer 98(3):645-55, 8/2003. PMID: 12879484.
73. Rubenstein EB, Rolston K, Benjamin RS, Loewy J, Escalante C, Manzullo E, Hughes P, Moreland B, Fender A, Kennedy K, Holmes F, Elting L, Bodey GP. Outpatient treatment of febrile episodes in low-risk neuturopenic patients with cancer. Cancer 71(11):3640-3646, 6/2003. PMID: Not in Pub Med.
74. Cantor SB, Elting LS, Hudson DV, Rubenstein EB. Pharmacoeconomic analysis of oprelvekin (recombinant human interleukin-11) for secondary prophylaxis of thrombocytopenia in solid tumor patients receiving chemotherapy. Cancer 97(12):3099-106, 6/2003. PMID: 12784347.
75. Elting LS, Cantor SB, Martin CG, Hamblin L, Kurtin D, Rivera E, Vadhan-Raj S, Benjamin RS. Cost of chemotherapy-induced thrombocytopenia among patients with lymphoma or solid tumors. Cancer 97(6):1541-50, 3/2003. PMID: 12627519.
76. Elting LS, Martin CG, Kurtin DJ, Cantor SB, Rubenstein EB, Rodriguez S, Kanesan K, Vadhan-Raj S, Benjamin RS. The Bleeding Risk Index: a clinical prediction rule to guide the prophylactic use of platelet transfusions in patients with lymphoma or solid tumors. Cancer 94:3252-62, 6/2002. PMID: 12115358.
77. Elting LS, Cantor SB. Outcomes and costs of febrile neutropenia: adventures in the science and art of treatment choices. Support Care Cancer 10(3):189-96, 4/2002. PMID: 11904783.
78. La Rosa AM, Champlin RE, Mirza N, Gajewski J, Giralt S, Rolston KV, Raad I, Jacobson K, Kontoyiannis D, Elting L, Whimbey E. Adenovirus infections in adult recipients of blood and marrow transplants. Clin Infect Dis 32(6):871-6, 3/2001. PMID: 11247710.
79. Schiffer CA, Anderson KC, Bennett CL, Bernstein S, Elting LS, Goldsmith M, Goldstein M, Hume H, McCullough JJ, McIntyre RE, Powell BL, Rainey JM, Rowley SD, Rebulla P, Troner MB, Wagnon AH, Wagnon AH. Platelet transfusion for patients with cancer: clinical practice guidelines of the American Society of Clinical Oncology. J Clin Oncol 19(5):1519-38, 3/2001. PMID: 11230498.
80. Elting LS, Rubenstein EB, Martin CG, Kurtin D, Rodriguez S, Laiho E, Kanesan K, Cantor SB, Benjamin RS. Incidence, cost, and outcomes of bleeding and chemotherapy dose modification among solid tumor patients with chemotherapy-induced thrombocytopenia. J Clin Oncol 19(4):1137-46, 2/2001. PMID: 11181679.
81. Escalante CP, Martin CG, Elting LS, Price KJ, Manzullo EF, Weiser MA, Harle TS, Cantor SB, Rubenstein EB. Identifying risk factors for imminent death in cancer patients with acute dyspnea. J Pain Symptom Manage 20(5):318-25, 11/2000. PMID: 11068153.
82. Elting LS, Rubenstein EB, Rolston K, Cantor SB, Martin CG, Kurtin D, Rodriguez S, Lam T, Kanesan K, Bodey G. Time to clinical response: an outcome of antibiotic therapy of febrile neutropenia with implications for quality and cost of care. J Clin Oncol 18(21):3699-706, 11/2000. PMID: 11054443.
83. Klastersky J, Paesmans M, Rubenstein EB, Boyer M, Elting L, Feld R, Gallagher J, Herrstedt J, Rapoport B, Rolston K, Talcott J. The Multinational Association for Supportive Care in Cancer risk index: A multinational scoring system for identifying low-risk febrile neutropenic cancer patients. J Clin Oncol 18(16):3038-51, 8/2000. PMID: 10944139.
84. Escalante CP, Kurtin D, Rivera E, Elting LS. Severity of illness, outcomes, and resource use in elderly cancer patients with deep venous thrombosis. Clin Appl Thromb Hemost 6(3):175-8, 7/2000. PMID: 10898279.
85. Jacobson K, Rolston K, Elting L, LeBlanc B, Whimbey E, Ho DH. Susceptibility surveillance among gram-negative bacilli at a cancer center. Chemotherapy 45(5):325-34, Sep-Oct, 9/1999. PMID: 10473920.
86. Elting LS, Martin CG, Cantor SB, Rubenstein EB. Influence of data display formats on physician investigators' decisions to stop clinical trials: prospective trial with repeated measures. BMJ 318(7197):1527-31, 6/1999. PMID: 10356010.
87. Elting LS, Rubenstein EB, Kurtin D, Rolston KV, Fangtang J, Martin CG, Raad II, Whimbey EE, Manzullo E, Bodey GP. Mississippi mud in the 1990s: risks and outcomes of vancomycin-associated toxicity in general oncology practice. Cancer 83(12):2597-607, 12/1998. PMID: 9874468.
88. Elting LS. Stratification in clinical trials of febrile neutropenia. Support Care Cancer 6(5):457-61, 9/1998. PMID: 9773463.
89. Rolston KV, Manzullo E, Elting L, Frisbee-Hume S, Rodriguez S, Rubenstein EB. Ambulatory management of varicella-zoster virus infection in immunocompromised cancer patients. Support Care Cancer 6(1):57-62, 1998. PMID: 9458538.
90. Sundararajan V, Rubenstein EB, Rolston KV, Elting LS. Controversies in new antibiotic therapy for ambulatory patients. Support Care Cancer 5(5):358-64, 9/1997. PMID: 9322346.
91. Elting LS, Rubenstein EB, Rolston KV, Bodey GP. Outcomes of bacteremia in patients with cancer and neutropenia: observations from two decades of epidemiological and clinical trials. Clin Infect Dis 25(2):247-59, 8/1997. PMID: 9332520.
92. Escalante CP, Martin CG, Elting LS, Rubenstein EB. Medical futility and appropriate medical care in patients whose death is thought to be imminent. Support Care Cancer 5(4):274-80, 7/1997. PMID: 9257423.
93. Yousuf HM, Englund J, Couch R, Rolston K, Luna M, Goodrich J, Lewis V, Mirza NQ, Andreeff M, Koller C, Elting L, Bodey GP, Whimbey E. Influenza among hospitalized adults with leukemia. Clin Infect Dis 24(6):1095-9, 6/1997. PMID: 9195063.
94. Bahmani A, Elting L, Tarrand J, Rolston K. Mycobacterium avium-complex (MAC) infection in cancer patients. Clinical Infectious Diseases 25:486, 1997. PMID: Not in Pub Med.
95. Libshitz HI, Pannu HK, Elting LS, Cooksley CD. Tuberculosis in cancer patients: an update. J Thorac Imaging 12(1):41-6, 1997. PMID: 8989758.
96. Martin CG, Kennedy KF, Elting LS, Manzullo E, Escalante CP, Rubenstein EB. Incidence of Emergency Visits Among Oncology Patients Receiving Outpatient Chemotherapy: Implications for Care in a Capitated Market. Cancer Control 3(5):435-441, 10/1996. PMID: 10764502.
97. Escalante CP, Martin CG, Elting LS, Cantor SB, Harle TS, Price KJ, Kish SK, Manzullo EF, Rubenstein EB. Dyspnea in cancer patients. Etiology, resource utilization, and survival-implications in a managed care world. Cancer 78(6):1314-9, 9/1996. PMID: 8826956.
98. Rolston KV, Elting L, Waguespack S, Ho DH, LeBlanc B, Bodey GP. Survey of antibiotic susceptibility among gram-negative bacilli at a cancer center. Chemotherapy 42(5):348-53, Sep-Oct, 9/1996. PMID: 8874974.
99. Mera JR, Whimbey E, Elting L, Preti A, Luna MA, Bruner JM, Williams T, Bodey GP, Goodrich JM. Cytomegalovirus pneumonia in adult nontransplantation patients with cancer: review of 20 cases occurring from 1964 through 1990. Clin Infect Dis 22(6):1046-50, 6/1996. PMID: 8783708.
100. Rubenstein EB, Fender A, Rolston KV, Elting LS, Prasco P, Palmer J, Road I, Pollock RE, Frisbee-Hume S, Laurence D. Vascular access by physician assistants: evaluation of an implantable peripheral port system in cancer patients. J Clin Oncol 13(6):1513-9, 6/1995. PMID: 7751900.
101. Elting LS, Whimbey E, Lo W, Couch R, Andreeff M, Bodey GP. Epidemiology of influenza A virus infection in patients with acute or chronic leukemia. Support Care Cancer 3(3):198-202, 5/1995. PMID: 7655781.
102. Whimbey E, Champlin RE, England JA, Mirza NQ, Piefra PA, Goodrich JM, Przepiorka D, Luna MA, Morice RC, Neumann JL, Elting LS, Bodey GP. Combination therapy with aerosolized ribavirin and intravenous immunoglobin for respiratory syncytial virus disease in adult bone marrow transplant recipients. Bone Marrow Transplantation 16:393-399, 1995. PMID: Not in Pub Med.
103. Elting LS, Rubenstein EB. The electronic medical record in a research institution: competing constituencies in a publish or perish world. Top Health Inf Manage 15(1):35-40, 8/1994. PMID: 10135721.
104. Samonis G, Elting L, Skoulika E, Maraki S, Tselentis Y. An outbreak of diarrheal disease attributed to Shigella sonnei. Epidemiol Infect 112(2):235-45, 4/1994. PMID: 8149998.
105. Bodey GP, Anaissie EJ, Elting LS, Estey E, O'Brien S, Kantarjian H. Antifungal prophylaxis during remission induction therapy for acute leukemia fluconazole versus intravenous amphotericin B. Cancer 73(8):2099-106, 4/1994. PMID: 8156515.
106. Whimbey E, Elting LS, Couch RB, Lo W, Williams L, Champlin RE, Bodey GP. Influenza A virus infections among hospitalized adult bone marrow transplant recipients. Bone Marrow Transplant 13(4):437-40, 4/1994. PMID: 8019468.
107. Rolston KV, Nguyen H, Amos G, Elting L, Fainstein V, Bodey GP. A randomized double-blind trial of vancomycin versus teicoplanin for the treatment of gram-positive bacteremia in patients with cancer. J Infect Dis 169(2):350-5, 2/1994. PMID: 8106768.
108. Lo W, Whimbey E, Elting L, Couch R, Cabanillas F, Bodey G. Antibody response to a two-dose influenza vaccine regimen in adult lymphoma patients on chemotherapy. Eur J Clin Microbiol Infect Dis 12(10):778-82, 10/1993. PMID: 8307050.
109. Whimbey E, Vartivarian SE, Champlin RE, Elting LS, Luna M, Bodey GP. Parainfluenza virus infection in adult bone marrow transplant recipients. Eur J Clin Microbiol Infect Dis 12(9):699-701, 9/1993. PMID: 8243487.
110. Bodey GP, Elting LS, Narro J, Koller C, O'Brien S, Estey E, Benjamin R. An open trial of cefoperazone plus sulbactam for the treatment of fever in cancer patients. J Antimicrob Chemother 32(1):141-52, 7/1993. PMID: 8226405.
111. Anaissie E, Kontoyiannis DP, Kantarjian H, Elting L, Robertson LE, Keating M. Listeriosis in patients with chronic lymphocytic leukemia who were treated with fludarabine and prednisone. Ann Intern Med 117(6):466-9, 9/1992. PMID: 1354425.
112. Elting LS, Bodey GP, Keefe BH. Septicemia and shock syndrome due to viridans streptococci: a case-control study of predisposing factors. Clin Infect Dis 14(6):1201-7, 6/1992. PMID: 1623076.
113. Raad I, Davis S, Khan A, Tarrand J, Elting L, Bodey GP. Impact of central venous catheter removal on the recurrence of catheter-related coagulase-negative staphylococcal bacteremia. Infect Control Hosp Epidemiol 13(4):215-21, 4/1992. PMID: 1593102.
114. Rolston KV, Berkey P, Bodey GP, Anaissie EJ, Khardori NM, Joshi JH, Keating MJ, Holmes FA, Cabanillas FF, Elting L. A comparison of imipenem to ceftazidime with or without amikacin as empiric therapy in febrile neutropenic patients. Arch Intern Med 152(2):283-91, 2/1992. PMID: 1739355.
115. Bodey GP, Elting LS, Rodriguez S. Bacteremia caused by Enterobacter: 15 years of experience in a cancer hospital. Rev Infect Dis 13(4):550-8, Jul-Aug, 7/1991. PMID: 1925270.
116. Bodey GP, Rodriguez S, Fainstein V, Elting LS. Clostridial bacteremia in cancer patients. A 12-year experience. Cancer 67(7):1928-42, 4/1991. PMID: 2004306.
117. Elting LS, Bodey GP. Is a picture worth a thousand medical words? A randomized trial of reporting formats for medical research data. Methods Inf Med 30(2):145-50, 4/1991. PMID: 1857251.
118. Bodey G, Reuben A, Elting L, Kantarjian H, Keating M, Hagemeister F, Koller C, Velasquez W, Papadopoulos N. Comparison of two schedules of cefoperazone plus aztreonam in the treatment of neutropenic patients with fever. Eur J Clin Microbiol Infect Dis 10(7):551-558, 1991. PMID: 1915397.
119. Samonis G, Anaissie E, Elting L, Bodey GP. Review of Citrobacter bacteremia in cancer patients over a sixteen-year period. Eur J Clin Microbiol Infect Dis 10(6):479-485, 1991. PMID: 1915382.
120. Khardori N, Elting L, Wong E, Schable B, Bodey GP. Nosocomial infections due to Xanthomonas maltophilia (Pseudomonas maltophilia) in patients with cancer. Rev Infect Dis 12(6):997-1003, Nov-Dec, 11/1990. PMID: 2267495.
121. Elting L, Bodey GP, Rosenbaum B, Fainstein V. Circadian variation in serum amikacin levels. J Clin Pharmacol 30(9):798-801, 9/1990. PMID: 2277126.
122. Elting LS, Bodey GP. Septicemia due to Xanthomonas species and non-aeruginosa Pseudomonas species: increasing incidence of catheter-related infections. Medicine (Baltimore) 69(5):296-306, 9/1990. PMID: 2402219.
123. Rolston KV, Bodey GP, Elting L. Aztreonam in the prevention and treatment of infection in neutropenic cancer patients. Am J Med 88(3C):24S-29S; discussion 38S-42S, 3/1990. PMID: 2180294.
124. Elting LS, Khardori N, Bodey GP, Fainstein V. Nosocomial infection caused by Xanthomonas maltophilia: a case-control study of predisposing factors. Infect Control Hosp Epidemiol 11(3):134-8, 3/1990. PMID: 2313082.
125. Karl C, Elting LS, Lindner K, Bodey GP. Implementation of a Fileman based system in a research setting. . MUG Quarterly 20:33-36, 1/1990. PMID: Not in Pub Med.
126. Bodey GP, Fainstein V, Elting LS, Anaissie E, Rolston K, Khardori N, Kantarjian H, Plager C, Murphy WK, Holmes F. Beta-lactam regimens for the febrile neutropenic patient. Cancer 65(1):9-16, 1990. PMID: 2403484.
127. Lindner KA, Whitten DJ, Elting LS, Bodey GP. Ntelligence: A fileman based expert system. MUG Quarterly 20:64-67, 1990. PMID: Not in Pub Med.
128. Bodey GP, Elting LS, Rodriquez S, Hernandez M. Klebsiella bacteremia. A 10-year review in a cancer institution. Cancer 64(11):2368-76, 12/1989. PMID: 2804929.
129. Saito H, Elting L, Bodey GP, Berkey P. Serratia bacteremia: review of 118 cases. Rev Infect Dis 11(6):912-20, Nov-Dec, 11/1989. PMID: 2602776.
130. Fainstein V, Berkey P, Elting L, Bodey GP. Haemophilus species bacteremia in patients with cancer. A 13-year experience. Arch Intern Med 149(6):1341-5, 6/1989. PMID: 2730252.
131. Fainstein V, Elting LS, Bodey GP. Bacteremia caused by non-sporulating anaerobes in cancer patients. A 12-year experience. Medicine (Baltimore) 68(3):151-62, 5/1989. PMID: 2716514.
132. Elting L, Riccardi S, Bodey GP. Data quality assurance in a multiuser medical research environment. MUG Quarterly 19:47-48, 1989. PMID: Not in Pub Med.
133. Bodey GP, Ho DH, Elting L. Survey of antibiotic susceptibility among gram-negative bacilli at a cancer hospital. Am J Med 85(1A):49-51, 7/1988. PMID: 3041819.
134. Anaissie EJ, Fainstein V, Bodey GP, Rolston K, Elting L, Kantarjian H, Cabanillas F, McCredie KB. Randomized trial of beta-lactam regimens in febrile neutropenic cancer patients. Am J Med 84(3 Pt 2):581-9, 3/1988. PMID: 3279774.
135. Elting LS, Bodey GP. Database design for medical research. MUG Quarterly 18:63-66, 1988. PMID: Not in Pub Med.
136. Bodey GP, Elting L, Jones P, Alvarez ME, Rolston K, Fainstein V. Imipenem/cilastatin therapy of infections in cancer patients. Cancer 60(2):255-62, 7/1987. PMID: 3297282.
137. Rolston KV, Jones PG, Fainstein V, Elting L, Bodey GP. Ceftizoxime plus ticarcillin: double beta-lactam therapy for infections in cancer patients. J Antimicrob Chemother 19(3):367-71, 3/1987. PMID: 3471752.
138. Fainstein V, Bodey GP, Elting L, Maksymiuk A, Keating M, McCredie KB. Amphotericin B or ketoconazole therapy of fungal infections in neutropenic cancer patients. Antimicrob Agents Chemother 31(1):11-5, 1987. PMID: 3566234.
139. Jones PG, Rolston KV, Fainstein V, Elting L, Walters RS, Bodey GP. Aztreonam therapy in neutropenic patients with cancer. Am J Med 81(2):243-8, 8/1986. PMID: 3526885.
140. Bodey GP, Elting L, Kassamali H, Lim BP. Escherichia coli bacteremia in cancer patients. Am J Med 81(1A):85-95, 7/1986. PMID: 3526883.
141. Elting LS, Bodey GP, Fainstein V. Polymicrobial septicemia in the cancer patient. Medicine (Baltimore) 65(4):218-25, 7/1986. PMID: 3724434.
142. Jones PG, Hopfer RL, Elting L, Jackson JA, Fainstein V, Bodey GP. Semiquantitative cultures of intravascular catheters from cancer patients. Diagn Microbiol Infect Dis 4(4):299-306, 4/1986. PMID: 3698543.
143. Jones P, Rolston K, Fainstein V, Elting L, Bodey GP. Aztreonam plus vancomycin (plus amikacin) vs. moxalactam plus ticarcillin for the empiric treatment of febrile episodes in neutropenic cancer patients. Rev Infect Dis 7(Suppl 4):S741-6, Nov-Dec, 11/1985. PMID: 3909332.
144. Fainstein V, Elting L, Pitlik S, Hortobagyi G, Keating M, Bodey GP. Ticarcillin plus clavulanic acid in the treatment of patients with cancer. Am J Med 79(5B):62-6, 11/1985. PMID: 4073096.
145. Bodey GP, Jadeja L, Elting L. Pseudomonas bacteremia. Retrospective analysis of 410 episodes. Arch Intern Med 145(9):1621-9, 9/1985. PMID: 3927867.
146. Rolston K, Guan Z, Bodey GP, Elting L. Acinetobacter calcoaceticus septicemia in patients with cancer. South Med J 78(6):647-51, 6/1985. PMID: 4001997.
147. Harris RL, Fainstein V, Elting L, Hopfer RL, Bodey GP. Bacteremia caused by Aeromonas species in hospitalized cancer patients. Rev Infect Dis 7(3):314-20, May-Jun, 5/1985. PMID: 4023526.
148. Bodey GP, Keating MJ, McCredie KB, Elting L, Rosenbaum B, Freireich EJ. Prospective randomized trial of antibiotic prophylaxis in acute leukemia. Am J Med 78(3):407-16, 3/1985. PMID: 3919579.
149. Rolston K, Bolivar R, Fainstein V, Jones P, Elting L, Bodey GP. Cefotaxime: single agent therapy for infections in cancer patients with adequate granulocyte counts. J Antimicrob Chemother 15(1):91-6, 1985. PMID: 3972760.
150. Fainstein V, Bodey GP, Bolivar R, Elting L, McCredie KB, Keating MJ. Moxalactam plus ticarcillin or tobramycin for treatment of febrile episodes in neutropenic cancer patients. Arch Intern Med 144(9):1766-70, 9/1984. PMID: 6383246.
151. Fainstein V, Bodey GP, McCredie KB, Keating MJ, Estey EH, Bolivar R, Elting L. Coagulation abnormalities induced by beta-lactam antibiotics in cancer patients. J Infect Dis 148(4):745-50, 10/1983. PMID: 6631064.
152. Fainstein V, Bodey GP, Elting L, Bolivar R, Keating MJ, McCredie KB, Valdivieso M. A randomized study of ceftazidime compared to ceftazidime and tobramycin for the treatment of infections in cancer patients. J Antimicrob Chemother 12(Suppl A):101-10, 7/1983. PMID: 6352612.
153. Bolivar R, Fainstein V, Elting L, Bodey GP. Cefoperazone for the treatment of infections in patients with cancer. Rev Infect Dis 5(Suppl 1):S181-7, Mar-Apr, 3/1983. PMID: 6221389.
154. Fainstein V, Bolivar R, Elting L, Valdivieso M, Bodey GP. Ceftizoxime in the treatment of infections in patients with cancer. J Antimicrob Chemother 10(Suppl C):167-73, 1982. PMID: 6296002.
155. Bodey, GP, Valdivieso M, Martin L. Cefoxitin therapy of infections in cancer patients. Curr Therap Res 9:294-300, 1981. PMID: Not in Pub Med.

Invited Articles
1. Svatek RS, Avritscher EB, Elting L, Dinney CP. High Risk Populations and Cystectomy Outcomes. J Urol. e-Pub 5/2009. PMID: 19450857.
2. Bensinger W, Schubert M, Ang KK, Brizel D, Brown E, Eilers JG, Elting L, Mittal BB, Schattner MA, Spielberger R, Treister NS, Trotti AM. NCCN Task Force Report. prevention and management of mucositis in cancer care. J Natl Compr Canc Netw 6(Suppl 1):S1-21; quiz S22-4, 1/2008. PMID: 18289497.
3. Elting LS. Annual Meeting Summaries: Health Services Research Abstracts. American Society of Clinical Oncology:117-123, 2005.
4. Elting LS, Keefe DMK, Sonis ST. Treatment-induced Gastrointestinal Toxicity in Patients with Cancer. American Society of Clinical Oncology, 2004 Educational Book, 2004.
5. Elting LS. Integrating Prophylactic Measures into Practice Guidelines for Platelet Growth Factors. Oncology 13:587-589, 1999. PMID: Not in Pub Med.
6. Rubenstein E, Wade JC, Adams P, Brown A, Elting L, Finberg R, Greene J, King E, Lipman B, Mendez P, Miller CB, Montoya J, Noskin G, Reed E, Rolston K, Talcott J, Zabner R. NCCN practice guidelines for fever and neutropenia. Oncology 13:197-257, 1999. PMID: Not in Pub Med.
7. Rubenstein EB, Elting L. Incorporating new modalities into practice guidelines: Platelet Growth Factors. Oncology (Williston Park) 12(11A):381-6, 11/1998. PMID: 10028521.
8. Goepfert, H, Elting L, Martin C. Editorial Review - Inclusion of Comorbidity in a Staging System for Head and Neck Cancer. Oncology 9:841-845, 1995. PMID: Not in Pub Med.
9. Elting, LS, Kurtin D. Here Today, Gone Today: The Challenges of Outpatient Supportive Care Research. Cancer Bulletin 47:305-309, 1995. PMID: Not in Pub Med.
10. Rubenstein EB, Elting LS. Pharmacoeconomic analyses: whose perspective counts and costs the most? Am J Hosp Pharm 51(12):1564-9, 6/1994. PMID: 8092157.
11. Elting LS, Bodey GP. Evaluation of benefits derived from a computerized data management system for clinical trials data. Proc Annu Symp Comput Appl Med Care:48-52, 1991. PMID: 1807647.
12. Elting LS. Database Systems for Clinical Research: Information Driven Design. Proc. Amer Assoc for Medical Systems and Informatics:227-31, 1988. PMID: Not in Pub Med.
13. Elting LS, Lynn Davis A. Human Computer Interfaces: A Randomized Study of Data Entry and Editing Formats. Proc Symp on Computer Applications in Medical Care (SCAMC), 1988. PMID: Not in Pub Med.
14. Elting L, Lynn A, Bodey GP. Human/computer interfaces: A randomized trial of data entry and editing formats. Proceedings - Annual Symposium on Computer Applications in Medical Care:459-462, 1988. PMID: Not in Pub Med.
15. Lynn A, Elting LS. User Interface Design: A Study of Data Entry Methods. Proc. Amer Assoc for Medical Systems and Informatics:237-241, 1988. PMID: Not in Pub Med.
16. Bodey GP, Fainstein V, Rolston K, Elting L. Empiric Therapy for the Granulocytopenic Patient. Princeton: Wallace Communications. New Approaches to Antimicrobial Therapy, Proceedings of a Symposium:28-33, 1987. PMID: Not in Pub Med.
17. Rolston KV, Fainstein V, Elting L, Bodey GP. Single Agent Therapy of Infections in Patients with adequate Neutrophil Counts. Basel Switzerland. Proc Changing Concepts in Management of Serious Infectious:102-105, 1986. PMID: Not in Pub Med.
18. Rolston K, Bolivar R, Elting L, Bodey G. Emergence of Enterococci as Important Pathogens in Patients with Malignant Diseases. Ishigami J (ed): Recent Advances in Chemotherapy -Antimicrobial Section, Proc 14th International Congress of Chemotherapy, Kyoto, Japan. University of Tokyo Press, Tokyo. Recent Advances in Chemotherapy -Antimicrobial Section, Proc 14th International Congress of Chemotherapy, Kyoto, Japan:2006-2007, 1985.
19. Rolston K, Elting L, Bodey GP. Importance of Coagulase Negative Staphylococci in Patients with Cancer. Recent Advances in Chemotherapy Anticancer Section, Proc 14th International Congress of Chemotherapy, Kyoto, Japan. University of Tokyo Press, Tokyo. Recent Advances in Chemotherapy Anticancer Section:2061 2062, 1985.

Abstracts
1. Suarez-Almazor, ME, Peddi P, Luo R, Nguyen H, Elting L. Low Rates of Bone Mineral Density Measurement in Men with Prostate Cancer Initiating Androgen Deprivation Therapy: A Population-Based Study of Medicare Beneficiaries in the State of Texas. ASCO's Quality Care Symposium: Quality Matters, San Diego, CA, 2012.
2. Elting L, Nguyen H, Irvin Vidrine J, Freedman R, Theriault R. Health Behaviors and Health Status of Cancer Survivors in Texas: A Statewide Study. Cancer Survivorship Research Symposium, UT MD Anderson Cancer Center, Houston, Texas, 1/2011.
3. Elting L On Behalf Of Cercit Investigators, Xu Y, Nguyen H. Adherence to National Guidelines for Prophylactic Use of Granuloctye Growth Factors among Elderly Texans with Non-Hodgkin's Lymphoma. Innovations In Cancer Prevention and Research Conference, Austin, TX, 2011.
4. Gomez D, Liao K, Nguyen H, Smith B, Elting L On Behalf of Cercit Investigators. An estimation of guideline adherence to nausea and vomiting prophylaxix in patients receiving systemic therapy for lung cancer. Innovations In Cancer Prevention and Research Conference, Austin, TX, 2011.
5. Suarez-Almazor M, Luo R, Nguyen H, Elting L On Behalf of Cercit Investigators. Measurement of Bone Mineral Density in Patients with Breast Cancer Initiating therapy with Aromatase Inhibitors: Low Utilization and Ethnic Disparities. Innovations In Cancer Prevention and Research Conference, Austin, TX, 2011.
6. Parelkar P, Nguyen H, Elting E On Behalf of Cercit Investigators. Physical Inactivity Among Cancer Survivors Age 45-65 in Texas. Innovations In Cancer Prevention and Research Conference, Austin, TX, 2011.
7. Nguyen H, Elting L On Behalf of Cercit Investigators. Prevalence and Association of Health Behaviors and Cardiovascular Diseases among Adult Survivors of Childhood Cancer in the U S Population. Innovations In Cancer Prevention and Research Conference, Austin, TX, 2011.
8. Elting L, Lei X, Nguyen H, Keefe D, Sonis S. Risk of Patient-Reported Oral Mucositis During Chemotherapy For Colorectal Cancer (CRC): Do Multiple Cycles Multiply Risks?. Supportive Care in Cancer 19(Suppl 2: S67-S370):S215, 2011.
9. Holmes H, Nguyen H, Oh J, Escalante C, Vidrine J, Freedman R, Theriault R, Wetter L, Elting L On Behalf of Cercit Investigators. The Burden of Comorbid Illness in Cancer Survivors. Innovations In Cancer Prevention and Research Conference, Austin, TX, 2011.
10. Nguyen HT, Vidrine JI, Freedman RS, Theriault RL, Wetter DW, Elting LS. The Burden of Comorbid Illness in Cancer Survivors in the United States. Supportive Care in Cancer 19(Suppl 2:S67-S370):196-7, 2011.
11. Avritscher EBC, Cooksley C, Rolston K, Swint JM, Delclos G, Franzini L, Swisher S, Walsh G, Mansfield P, Elting L. Comparative Effectiveness Research in Texas: Clinical and Economic Outcomes of Serious Postoperative Infections following Resection of Respiratory and Gastrointestinal Solid Tumors. 2010 Cancer Prevention and Research Institute of Texas (CPRIT) Conference, Austin, Texas, 11/2010.
12. Shroff RT, Javle MM, Krishnan S, Cantor SB, Lee JE, Fleming JB, Varadhachary GR, Abbruzzese JL, Wolff RA, Elting LS. Cost-effectiveness of neoadjuvant (neoAdj) versus adjuvant (Adj) therapies for resectable pancreatic cancer (PC). 2010 Annual Meeting, Association of Clinical Oncology (ASCO), Chicago, Illinois, 2010.
13. Eschbach K, Cooksley C, Riall T, Elting L, Goodwin J. Cross-county travel for surgical procedures for cancer care in Texas. 2010 Cancer Prevention and Research Institute of Texas (CPRIT) Conference, Austin, Texas, 2010.
14. Nguyen H, Elting L. Current health behaviors among prostate and breast cancer survivors in Texas - findings from the 2010 Behavioral Risk Factors Surveillance System BRFSS. 2010 Cancer Prevention and Research Institute of Texas (CPRIT) Conference, Austin, Texas, 2010.
15. Sun CC, Jhingran A, Ramondetta LM, Eifel PJ, Crane CH, Phan AT, Urbauer D, Frumovitz MM, Elting LS, Bodurka DC. Gynecologic versus gastrointestinal patients: Preferences (prefs) over time for chemoradiation (chemoXRT) side effects (SE) using visual analog scale (VAS) and time trade-off (TTO). 2010 Annual Meeting, Association of Clinical Oncology (ASCO), Chicago, Illinois, 2010.
16. Elting L, Eberth J, Nguyen H. Is Mammography screening capacity in Texas sufficient to achieve cancer control goals?. 2010 Cancer Prevention and Research Institute of Texas (CPRIT) Conference, Austin, Texas, 2010.
17. Herbst R, Mims M, Schiller J, Karnad A, Reynolds C, Hellerstedt B, Campos L, Neumanaitis J, Ruud C, Kim E, Beaudet A, Gibbs R, Ayala G, Berry D, Hilsenbeck S, Buzdar A, Elting L, Poplack D. The Cancer Trials Network of Texas (CTNeT). 2010 Cancer Prevention and Research Institute of Texas (CPRIT) Conference, Austin, Texas, 2010.
18. Bodurka DC, Jhingran A, Ramondetta LM, Eifel PH, Crane CH, Phan AT, Urbauer D, Frumovitz MM, Elting LS, Sun CC. Visual analog scale (VAS) and time trade-off (TTO) preferences for side effects (SE) of chemoradiation (chemoXRT): A comparison of patients (pts) and caregivers (CG). 2010 Annual Meeting, Association of Clinical Oncology (ASCO), Chicago, Illinois, 2010.
19. Avritscher EBC, Shih TY, Sun CC, Gralla RJ, Grunberg SM, Xu Y, Elting LS. Cost-Effectiveness Analysis of Palonosetron-Based Therapy Compared with Ondansetron-Based Therapy in Prevention Emesis among Breast Cancer Patients Receiving Chemotherapy with Anthracycline and Cylophosphamide. 10th Annual Health Services & Outcomes Research Conference, Kelsey Research Foundation, Houston, Texas, 12/2009.
20. Avritscher EBC, Cooksley CD, Bekele BN, Rolston KV, Elting LS. Clinical and Economic Impact of Hospitalization for Methicillin-Resistant Staphylococcus Aureas Infections among Community-Dwelling Cancer Patients in Texas. 84th Annual Conference, Texas Public Health Association (TPHA), San Antonio, Texas, 4/2009.
21. Sun CC, Ramondetta LM, Jhingran A, Eifel PJ, Crane C, Phan AT, Frumovitz MM, Elting LS, Bodurka DC. Patient preferences for chemoradiation-related side effects. 2009 Annual Meeting, Association of Clinical Oncology (ASCO), Orlando, Florida, 2009.
22. Avritscher EBC, Cooksley CD, Bekele BN, Rolston KV Elting LS. Clinical and Economic Impact of Hospitalization for Methicillin-Resistant Staphylococcus aureus Infections among Community-Dwelling Cancer Patients in Texas. 9th Annual Health Services & Outcomes Research Conference, Kelsey Research Foundation, Houston, Texas, 12/2008.
23. Cooksley CD, Avritscher EBC, Elting LS. Inpatient Admissions for Infection in Cancer Patients: Impact of an Aging Population. 136th Annual Meeting, American Public Health Association (APHA), San Diego, California, 10/2008.
24. Avritscher E, Cooksley C, Bekele BN, Rolston K, Elting L. Clinical and Economic Impact of Hospitalization for Methicillin-Resistant Staphylococcus Aureas Infections among Community-Dwelling Cancer Patients in Texas. 2008 International Symposium, Multinational Association for Supportive Care in Cancer (MASCC), Houston, Texas, 2008.
25. Barasch A, Spijkervet F, Garden A, Kudrimoti MR, Brachman D, Brennan M, Tischler RB, Elting L, Keefe D, Sonis S. Efficacy of opioid analgesics and effect on functional status of pain caused by radiation-induced mucositis among patients with head and neck cancer. 2008 Annual Meeting, American Society of Clinical Oncology (ASCO), Chicago, Illinois, 2008.
26. Cardenas-Turanzas M, Cooksley C, Kamat AM, Pettaway CA, Elting LS. Gender and Age Differences in Blood Utilization and Length of Stat in Radical Cystectomy: A Population Based Study. 8th Annual Conference of The Texas Public Health Association (TPHA), San Antonio, Texas, 2008.
27. Cooksley CD, Avritscher EBC, Elting LS. Inpatient Admissions for Infection in Cancer Patients: Impact of an Aging Population. 84th Annual Conference of the Texas Public Health Association (TPHA), San Antonio, Texas, 2008.
28. Shih Ya-Chen Tina, Xu Ying, Elting Linda. Outpatient Use of Hematopoietic Colony Stimulating Factors (Csf) Among Elderly Cancer Patients with Chemotherapy. 2008 Multinational Association for Supportive Care in Cancer (MASCC), Houston, Texas, 2008.
29. Barasch A, Spijkervet F, Brennan M, Elting L, Keefe D, Sonis S. Pain Caused by Radiation-Induced Mucositis Is Debilitating and Poorly Controlled by Opioid Analgesics Among Patients with Head and Neck Cancer. 2008 Multinational Association for Supportive Care in Cancer (MASCC), Houston, Texas, 2008.
30. Sun Charlotte, Aguilliard Jawana, Jhingran Anuja, Phan Alexandra, Elting Linda, Bodurka Diane. Preferences for Side-Effects of Chemoradiation: Focus on Nausea and Vomiting. 2008 Multinational Association for Supportive Care in Cancer (MASCC), Houston, Texas, 2008.
31. Sonis S, Jacquin P, Randolph r, Harari P, Grunberg S, Liao Z, Bolek T, Elting L, Keefe D. Prevalence of mouth and throat soreness in patients undergoing lung cancer treatment, with adverse impact on functional and quality of life outcomes. 2008 American Society for Therapeutic Radiation Oncology (ASTRO) Annual Meeting, Boston, Massachusetts, 2008.
32. Avritscher EBC, Cooksley CD, Elting L. Risk and Outcomes of Serious Postoperative Infections among Cancer Patients with Solid Tumors. 84th Annual Conference, The Texas Public Health Association (TPHA), San Antonio, Texas, 2008.
33. Cardenas-Turanzas Marylou, Tovalin-Ahmumada Horacio, Carillo Maria Teresa , Paez-Aguirre Sandra, Elting Linda. The Place of Death of Children with Cancer In the Metropolitan Areas of Mexico. 2008 Multinational Association for Supportive Care in Cancer (MASCC), Houston, Texas, 2008.
34. Keefe D, Elting S, Sonis A, Garden A, Spijkervet F, Barasch A, Jacquin P, Randolph P, Harari P. Treatment for Head and Neck Cancer or Lung Cancer Causes Significant Diarrhea. 2008 American Society for Therapeutic Radiation Oncology (ASTRO) Annual Meeting, Boston, Massachusetts, 2008.
35. Cooksley CD, Avritscher EBC, Elting LS. Bladder Cancer in the Elderly: Racial/Ethnic Distribution of Resource Utilization. 135th Annual Meeting, American Public Health Association (APHA), Washington, DC, 11/2007.
36. Elting LS, Avritscher EBC, Cooksley CD. Impact of Postoperative Infections on the Use of Hospital Resources and Hospital Cost Among Cancer Patients. 2007 International Symposium, Multinational Association for Supportive Care in Cancer (MASCC), St. Gallen, Switzerland, 6/2007.
37. Avritscher EBC, Cooksley CD, Geraci J, Bekele B, Cantor S, Rolston K, Elting LS. Cost-Effectiveness of Influenza Vaccination in Working-Age Cancer Patients. 82nd Annual Meeting, Texas Public Health Association (TPHA), Galveston, Texas, 2/2007.
38. Lovell K, Cooksley CD, Avritscher EBC, Shih YS, Elting LS. Medicare Coverage and Colonoscopy Screening: Who is Really Benefiting?. 82nd Annual Meeting, Texas Public Health Association (TPHA), Galveston, Texas, 2/2007.
39. Elting LS, Avritscher EBC, Cooksley CD. Impact of Postoperative Infections on the Use of Hospital Resources and Hospital Cost among Cancer Patients. 2007 International Symposium, Multinational Association for Supportive Care in Cancer (MASCC), St. Gallen, Switzerland, 2007.
40. Garden A, Tishler R, Barasch A, Brennan M, Harari P, Kudrimoti M, Schultz C, Brachman D, Oster G, Vera-Llonch M, Keefe D, Sonis S, Elting L and the Triad BOI Head and Neck Group. Mouth and Throat Soreness Associated with Mucositis: Major Impact on Resource Use and Health Related Quality of Life Outcomes in Head and Neck Cancer Patients Receiving Radiation. 2007 American Society for Therapeutic Radiation Oncology (ASTRO) Annual Meeting, Los Angeles, California, 2007.
41. Keefe DM, Garden A, Barasch A, Tischler R, Brennan M, Trotti A, Vera-Llonch M, Oster G, Elting L, Sonis S. Oral mucositis is associated with increased resource use among patients receiving treatment for cancers of the head and neck. 2007 Annual Meeting, American Society of Clinical Oncology (ASCO), Chicago, Illinois, 2007.
42. Elting LS, Calais G, Selva N, Brachman D, Kudrimoti M, Spijkervet F, Vera-Llonch M, Oster G, Keefe D, Sonis ST, Triad BOI Head and Neck Group. Patient-reported burden of mucosal injury (MUI): Comparison of clinician-rated MUI and patient-reported outcomes. 2007 Annual Meeting, American Society of Clinical Oncology (ASCO), Chicago, Illinois, 2007.
43. Avritscher EBC, Cooksley CD, Elting LS,. Risk and Outcomes of Serious Postoperative Infections among Patients with Solid Tumors. 2007 International Symposium, Multinational Association for Supportive Care in Cancer (MASCC), St. Gallen, Switzerland, 2007.
44. Avritscher E, Cooksley C, Geraci J, Bekele B, Cantor S, Rolston K, Elting L. Cost-effectiveness Influenza Vaccination in Working-Age Cancer Patients. 7th Annual Health Services & Outcomes Research Conference. Kelsey Research Foundation, Houston, Texas, 11/2006.
45. Cardenas-Turanzas M, Carrillo M, Tovalin-Ahumada H, Elting L. Place of Death of Cancer Patients in the Metropolitan Area of Mexico City. 7th Annual Health Services & Outcomes Research Conference. Kelsey Research Foundation, Houston, Texas, 11/2006.
46. Elting LS. Best Practices for Oral Mucositis: Evaluating New Evidence and Exploring Management Strategies. 2006 International Symposium, Multinational Association for Supportive Care in Cancer (MASCC), Toronto, ON Canada, 6/2006.
47. Elting L, Keefe D, Sonis S, Morales M, Molassiotis A, Isitt j, Mayne T, Oster G, Vera-Llonch M. Burden of illness and Economic Impact of Mucosal Injury (MUI) in Solid Tumor - A Multinational Prospective Observational Study design. 31st European Society for Medical Oncology (ESMO) Conference, 2006.
48. Elting L, Keefe D, Sonis S, Selva-Nagayam S, Isitt J, Mayne T, Oster G, Vera-Llonch M. Burden of Illness of Mucosal Injury in Solid Tumor and Lymphoma from the Patient's Perspective-A Multinational Prospective Observational Study Design. 2006 Annual Meeting, Clinical Oncology Society of Australia (COSA), Melbourne, Australia, 2006.
49. Avritscher EB, Cooksley CD, Garaci JM, Bekele BN, Cantor SB, Rolston KV, Elting LS. Cost-effectiveness of influenza vaccination of adult cancer patients. 2006 American Society of Clinical Oncology (ASCO) Annual Meeting, Atlanta, Georgia, 2006.
50. Elting L, Cooksley CD, Johnson K, Shih, YCT. Disparities in Access to Mammography Facilities in Texas and Associated Breast Cancer Mortality. 81st Annual Meeting, Texas Public Health Association (TPHA), 2006.
51. Cooksley DC, Avritscher EBC, Elting LS. Epidemiology of Serious Influenza Infections in Cancer Patients. 133rd Annual Meeting & Exposition, American Public Health Association (APHA), Philadelphia, PA, 12/2005.
52. Avritscher, E, Cooksley C, Grossman H, Sabuchi A, Hamblin L, Elting LS. A Clinical Model of the Lifetime Cost of Treating Bladder Cancer and Associated Complications. 2005 International Symposium, Multinational Association for Supportive Care in Cancer (MASCC), Geneva Switzerland, 6/2005.
53. Elting, LS, Cooksley C, Garden A. Clinical Outcomes of Radiotherapy-Induced Oral Mucositis among Patients with Head and Neck Cancers. 2005 International Symposium, Multinational Association for Supportive Care in Cancer (MASCC), Geneva Switzerland, 6/2005.
54. Elting, LS, Cooksley C, Garden A. Economic Burden of Radiotherapy-Induced Oral Mucositis among Patients with Head and Neck Cancers. 2005 International Symposium, Multinational Association for Supportive Care in Cancer (MASCC), Geneva Switzerland, 6/2005.
55. Jones, J, Qazilbash M, Shih YCT, Cantor S, Cooksley C, Elting LS. Economic Implication of Outcomes Complicating Hematopoietic Stem Cell Transplant (HSCT) for Multiple Myeloma, Hodgkin's disease and Non-Hodgkin's Lymphoma. 2005 International Symposium, Multinational Association for Supportive Care in Cancer (MASCC), Geneva Switzerland, 6/2005.
56. Cooksley, C, Avritscher E, Elting LS. Epidemiology of Serious Influenza Infections in Cancer Patients. 2005 International Symposium, Multinational Association for Supportive Care in Cancer (MASCC), Geneva Switzerland, 6/2005.
57. Elting, L, Lu C, Escalante C, Giordano S, Trent J, Avritscher E, Gralla R Talcott J Rolston K. Safety and Effectiveness of Outpatient therapy in 596 Low-risk Patients with Febrile Neutropenia. 2005 Annual Meeting, American Association of Clnical Oncology (ASCO), Orlando, Florida, 5/2005.
58. Cooksley DC, Elting LS, Avritscher EBC, Murakami Y. Burden of Vaccine Preventable Respiratory Diseases in the Cancer Population: Global Estimates Based on Texas Inpatient Experience. 80th Annual Conference, Texas Public Health Association (TPHA), Odessa, Texas, 4/2005.
59. Elting LS, Bekele BN, Cooksley Dc, Avritscher EBC, Cantor SB, Shih YCT. Race, Ethnicity and Disparities in Access to High Quality Surgical Oncology Providers in Texas. 80th Annual Conference, Texas Public Health Association (TPHA), Odessa, Texas, 4/2005.
60. Shih, YCT, Han S, Zhao L, Elting LS. Economic Burden of Uncontrolled Chemotherapy-induced Nausea and Vomiting among Working-Age Cancer Patients. 2005 American Association of Clinical Oncology (ASCO) Annual Meeting, Orlando, FL, 2005.
61. Jones JA, Qazibash MH, Shih YT, Cantor SB, Cooksley CD, Elting LS. Economic Implication of Outcomes Complicating Hematopoetic Stem Cell Transplant (HSCT) for Multiple Myeloma (MM), Hodgkin's (HD) and Non-Hodgkin's Lyhmphoma (NHL). 2005 American Association of Clinical Oncology (ASCO) Annual Meeting, Orlando, FL, 2005.
62. Cooksley CD, Avritscher EC, Bekele BN, Jones JA, Elting LS. Epidemiology and Outcomes of Serious Influenza Infections in Lung Cancer Patients. 2005 American Association of Clinical Oncology (ASCO) Annual Meeting, Orlando, FL, 2005.
63. Elting, LS, Shih YCT, Stiff PJ, Bensinger W, Cantor SB, Cooksley C, Spielberger R. Palifermin Reduces Estimated Downstream Costs of Autologous Stem Cell Transplant: Analysis of Phase 3 Trial Results. American Society of Hematology 46th Annual Meeting and Exposition. San Diego, CA, 12/2004.
64. Elting, LS, Cooksley C, Pettaway C, Bekele BN, Avritscher EBC, Grossman HB, Mansfield P, Dinney CPN. The volume-staffing-outcome relationship: A population-based study of moderate-risk cancer surgery. 10th Annual Meeting of the American Society of Clinical Oncology, New Orleans, LA (#6025), 6/2004.
65. Smith, DL, Raut CP, Elting LS, Mansfield. Volume-outcome relationship of gastrectomy for cancer in Texas. 40th Annual Meeting of the American Society of Clinical Oncology, New Orleans, LA (#6091), 6/2004.
66. Elting, LS, Bekele BN, Cooksley CD, Avritscher EBC, Cantor SB, Shih YCT. Race, Ethnicity, and Access to High Quality Surgical Oncology Services: A Population-Based Study. 9th Biennial Symposium on Minorities, the Medically Underserved & Cancer. Washington, DC, 3/2004.
67. Elting, LS, Cooksley C, Pettaway C, Bekele BN, Avritscher EBC, Grossman HB, Mansfield P, Dinney CPN. Registered nurse staffing and outcomes: A population-based study of moderate-risk cancer surgery in Texas. Appendix to the 2005-2010 Texas State Health Plan, 2004.
68. Avritscher, EBC, Shih YCT, Elting LS. Clinical Outcomes and Economic Impact of Inpatient Care for Cancer Therapy-Induced Myelossupression in Texas. Houston Area HSR Conference proceedings, 11/2003.
69. Zhao, L, Bekele BN, Cooksley C, Elting LS. Comparison of Modeling Methods for Hierarchical Data in Health Services Research. Houston Area HSR Conference proceedings, 11/2003.
70. Amos, CE, Elting LS. Cystoscopy and the Development of Invasive Bladder Cancer in Patients Presenting with Superficial Urinary Bladder Cancer. Houston Area HSR Conference proceedings, 11/2003.
71. Hunt, T, Beaumont J, Webster K, Cella D, Elting L. Development and Validation of a Brief Self-Report Questionnaire Specific to Thrombocytopenia: The Functional Assessment of Cancer Therapy-Thrombocytopenia (FACT-Th) Questionnaire. 10th Annual Conference of the International Society for Quality of Life Research, Prague, Czech Republic, 11/2003.
72. Cooksley, C, Elting LS, Murakami Y. Impact of Vaccine Preventable Respiratory Infections: Why Immunization Programs for Those Age 50 and Older Make Sense. Houston Area HSR Conference proceedings, 11/2003.
73. Elting, LS, Shih YCT. Challenges of Supportive care of Cancer Patients. MASCC's 15th International Symposium on Supportive Care in Cancer, Berlin, Germany,, 6/2003.
74. Elting, LS, Pettaway CA, Grossman HB, Bekele BN, Cooksley C, Caramel E, Abbruzzese JL, Dinney CPN. Gatekeeping and access to high volume hospitals for cancer surgery: A population based study. 39th Annual Meeting of the American Society of Clinical Oncology, Chicago, Illinois (#2114), 5/2003.
75. Price, KJ, Amos C, Bekele BN, Feeley T, Ware C, Elting LS. Outcomes of Mechanical Ventilation Among Lung Cancer Patients. 39th Annual Meeting of the American Society of Clinical Oncology, Chicago, Illinois (#2210), 5/2003.
76. Bekele, BN, Swisher S, Zhou X, Cooksley C, Elting LS. Relationship Between Postoperative In-Hospital Mortality and Hospital Volume of Esophagectomy: The Effect of Centers of Experience in Texas. 39th Annual Meeting of the American Society of Clinical Oncology, Chicago, Illinois (#2115), 5/2003.
77. Saldin, KR, Mansfield P, Elting LS. The Influence of Hospital Volume on Inpatient Mortality Following Gastrectomy. 39th Annual Meeting of the American Society of Clinical Oncology, Chicago, Illinois (#2146), 5/2003.
78. Elting LS, Pettaway C, Bekele BN, Grossman HB, Cooksley C, Caramel E, Saldin K, Abbruzzese J, Dinney CPN. Gatekeeping and Access to High-Quality Healthcare Providers for Cancer Surgery in Texas: A Population-Based Study. TPHA's 78th Annual Educational Conference, San Antonio, Texas. 4/2003.
79. Elting, LS, Pettaway CA, Grossman HB, Bekele BN, Saldin KR, Dinney CPN. Relationship Between Postoperative In-Hospital Mortality and Annual Hospital Volume of Cystectomies: The Effect of Centers of Experience. American Urological Association, Chicago, IL, 4/2003.
80. Saldin, KR, Mansfield PF, Elting LS. Volume of Gastrectomies and Postoperative Mortality in Texas. The effect of centers of experience. TPHA's 78th Annual Educational Conference, San Antonio, Texas, 2003.
81. Abbott, BD, Rivera E, Escalante CP, Elting LS, Greenberg L, Michaud L, Hortobagyi GN. A Pilot Study of Subcutaneous Dalteparin for Outpatient Treatment of Deep Venous Thrombosis (DVT) in Breast Cancer Patients. 38th Annual Meeting of the American Society of Clinical Oncology, Orlando, Florida (#2841), 5/2002.
82. Mathew, P, Elting LS, Owen S, Lin J. Cancer in the Prison Population. 38th Annual Meeting of the American Society of Clinical Oncology, Orlando, Florida (#2591), 5/2002.
83. Elting, LS, Cooksley C, Chambers M, Martin C, Manzullo E, Rubenstein E. Outcomes of Oral Mucositis Among Cancer Patients. Supportive Care in Cancer 10 (#34), 5/2002.
84. Elting, LS, Cooksley C. Survival Benefits of Clinical Trials Compared to Conventional Therapy for Cancer. 38th Annual Meeting of the American Society of Clinical Oncology, Orlando, Florida (#988), 5/2002.
85. Caramel, EB, Cantor SB, Escalante CP, Rivera E, Elting LS. Cost-Minimization Analysis of Low-Molecular-Weight Heparin (Dalteparin) Compared to Unfractionated Heparin for Inpatient Care of Cancer Patients with Deep Venous Thrombosis. Houston Area HSR Conference proceedings, 2002.
86. Elting LS, Cooksley C, Adams J, Wahed T, Cohen D, Bennett C. Factors Affecting Decisions to Prescribe Erythropoietin: Update on the ASCO/ASH/MASCC Survey. Supportive Care in Cancer 9:4 (#3), 6/2001.
87. Adams JR, Elting LS, Lyons T, Demetri GB, Lembersky BC, Bennett CL. Evaluation of EPO Use and Direct-To-Consumer Marketing Effects: Results from a Survey of American and International Hematologists and Oncologists. 37th Annual Meeting of the American Society of Clinical Oncology, San Francisco, California (#994), 5/2001.
88. Elting LS, Martin CG, Hamblin L, Chau Q, Kurtin D. Impact of Throbocytopenia (TCP) on Total Cost of Chemotherapy (Chemo). 37th Annual Meeting of the American Society of Clinical Oncology, San Francisco, California (#965), 5/2001.
89. Cooksley, CD, Elting LS, Morris M. Mammography – Who is Being Screened? Differences Between Race/Ethnic Groups. 37th Annual Meeting of the American Society of Clinical Oncology, San Francisco, California (#979), 5/2001.
90. Elting, LS, Cantor, SB. Outcomes and Costs of Febrile Neutropenia. Abstracted in the annual proceedings from the Multinational Association for Supportive Care in Cancer (MASCC), Copenhagen, Denmark, 2001.

Book Chapters
1. Elting LS, Chang YC, Parelkar P. Epidemiology and outcomes of regimen-related toxicities. In: The Biological Basis for Regimen-related Toxicities of Cancer Treatment. Springer. In Press.
2. Avritsher EBC, Parelkar P, Chang YC, Elting LS. Quality of Life and Economic Outcomes of Nausea and Vomiting. In: Nausea: A practical guide to clinical management. Cambridge University Press. In Press.
3. Elting LS, Paesmans M. Controversies and Quandries: The Design of Clinical Trials in Febrile Neutropenia. IN: Rubenstein EB and Rolston KVI, Eds. In: Fever in the Neutropenic Cancer Patient. Martin Dunitz, Ltd., 45-55, 2001.
4. Rubenstein EB, Elting LS, Sun CC, Rolston KVI. Outpatient management of neutropenic fever: Antibiotics, growth factors or both? IN: Wingard J, Demetri G, Eds. In: Clinical Applications of Cytokines and Growth Factors. Kluwer Academic Publishers, 159-177, 1999.
5. Bodey G, Rodriguez V, Freireich E, et al. Protected Environments. IN: Burchenal JH, Oettgen HF (Eds). In: Cancer Achievements, Challenges and Prospects for the 1980s. Grune and Stratton, 699-710, 1981.

Letters to the Editor
1. Elting LS, Cantor SB. Author Reply. The Burdens of Cancer Therapy: Clinical and Economic Outcomes of Chemotherapy-Induced Mucositis. Cancer 100:1325-1326, 2004.
2. Rolston KV, Elting LS, Bodey GP. Bacteremia due to viridans streptococci in neutropenic patients. Am J Med 99(4):450, 1995. PMID: 7573114.
3. Rubenstein EB, Elting LS. Re-examination of clinical aspects of pharmacoeconomic analysis. Am J Hosp Pharm 51(23):2970-3, 12/1/1994. PMID: 7879813.
4. Rubenstein EB, Elting LS. Re-examination of clinical aspects in pharmacoeconomic analysis. Am J Hosp Pharm 51(23):2970-3, 12/1994. PMID: 7879813.
5. Rubenstein EB, Rolston K, Elting L. Outpatient antibiotic therapy in febrile neutropenic patients undergoing high-dose chemotherapy and autologous bone marrow support. J Clin Oncol 12(11):2516-1517, 11/1994. PMID: 7964970.
6. Rubenstein EB, Rolston K, Benjamin RS, Loewy J, Escalante C, Manzullo E, Hughes P, Moreland B, Fender A, Kennedy K. Outpatient treatment of febrile episodes in low-risk neutropenic patients with cancer. Cancer 71(11):3640-6, 6/1993. PMID: 8490912.
7. Haron E, Bodey GP, Luna MA, Dekmezian R, Elting L. Has the incidence of Pneumocystis carinii pneumonia in cancer patients increased with the AIDS epidemic? Lancet 2(8616):904-905, 1988. PMID: 2902342.

Grant & Contract Support

Title: Monoclonal Antibodies in Cancer Care: Is Underinsurance an Access Barrier?
Funding Source: NIH/AHRQ Subcontract from University of Chicago
Role: Co-Investigator
Principal Investigator: Ya-Chen Tina Shih
Duration: 9/1/2011 - 8/31/2013
 
Title: Health Status and Health Behaviors among Cancer Survivors: A population-based study
Funding Source: The University of Texas M D Anderson Cancer Center
Role: Principal Investigator
Duration: 7/15/2011 - 8/15/2013
 
Title: Cost-of-Illness of Chemotherapy-induced Diarrhea in Cancer Patients
Funding Source: TRIAD Burden of Illness, Inc.
Role: Principal Investigator
Duration: 11/8/2010 - 11/30/2014
 
Title: CERCIT: Comparative Effectiveness Research on Cancer in Texas (P01)
Funding Source: Cancer Prevention & Research Institute of Texas (CPRIT) Subcontract from UTMB
Role: Principal Investigator-MDACC
Principal Investigator: James Goodwin
Duration: 8/1/2010 - 7/31/2013
 
Title: CERCIT: Comparative Effectiveness Research on Cancer in Texas (P04)
Funding Source: Cancer Prevention & Research Institute of Texas (CPRIT)
Role: Principal Investigator-MDACC
Principal Investigator: James Goodwin
Duration: 8/1/2010 - 7/31/2013
 
Title: CERCIT: Comparative Effectiveness Research on Cancer in Texas (C02)
Funding Source: Cancer Prevention & Research Institute of Texas (CPRIT) Subcontract from UTMB
Role: Principal Investigator-MDACC
Principal Investigator: James Goodwin
Duration: 8/1/2010 - 7/31/2013
 
Title: CERCIT: Comparative Effectiveness Research on Cancer in Texas (C04)
Funding Source: Cancer Prevention & Research Institute of Texas (CPRIT) Subcontract from UTMB
Role: Principal Investigator-MDACC
Principal Investigator: James Goodwin
Duration: 8/1/2010 - 7/13/2013

Last updated: 5/6/2013